Received: 15 April 2021
Accepted: 6 March 2022
First Online: 15 March 2022
: The present study was a part of Phase III clinical trial (ClinicalTrials.gov Identifier: NCT02448979) sponsored by the Institutional Review Board of Cancer Hospital, Chinese Academy of Medical Science and received ethics board approval (NCC2014 ZC-01).
: Not applicable.
: The authors declare that they have no competing interests.